Is PBH a good stock to buy right now?

Based on our 6-factor quantitative model, Prestige Consumer Healthcare Inc. (PBH) receives a "Reduce" rating with a composite score of 40.3/100. It is ranked #2,870 out of 4,446 stocks. Key factor scores: Quality 49/100, Value 48/100, Momentum 29/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for PBH?

Prestige Consumer Healthcare Inc. (PBH) has a "Reduce" rating and 2-star score. The composite score of 40.3 ranks it #2,870 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is PBH in?

Prestige Consumer Healthcare Inc. operates in the Healthcare sector (Pharmaceutical Products industry) with a market cap of $2.73 billion. It is classified as a mid-cap stock.

Does PBH pay a dividend?

PBH does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is PBH's P/E ratio?

PBH has a trailing P/E ratio of 13.80x. The Healthcare sector average is 23.6x. This below-average P/E may indicate the stock is undervalued.

How profitable is PBH?

PBH's quality factor score is 49/100. Gross margin: 55.6%. ROE: 10.4% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is PBH valued compared to peers?

PBH's value factor score is 48/100 (higher = cheaper). Key multiples: P/E 13.8x, EV/EBITDA 11.5x. Valuation is roughly in line with peers.

What is PBH's debt level?

PBH's debt-to-equity ratio is 56%. Sector average: 32%. Moderate leverage is normal for established companies.

PBH has a beta of 0.48, meaning it is less volatile than the market. Stability score: 72/100.

Does PBH have high short interest?

PBH's short interest factor score is 11/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

PBH Stock Analysis: Top Mid-Cap Reduce (Score 40.3/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
PBH	-0.37%	+7.76%	-13.53%	-8.33%	-29.93%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-0.30%	+4.15%	-13.87%	-7.97%	-59.46%	-	-	-
Alpha vs Sector	+0.98%	+7.41%	-9.72%	-3.49%	-39.14%	-	-	-

Metric	PBH	Benchmark
P/E Ratio	13.8x	-42%
EV/EBITDA	11.5x	+82%
Price / Book	1.4x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
PBH Prestige Consumer Healthcare Inc.	40	49	48	29	13.8x	10.4%	55.6%	17.5%	6.1%	56.0x	$2.7B

Key Ratio	TTM	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017
Gross Margin %	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.2%	0.6%
Operating Margin %	0.3%	0.3%	0.3%	0.3%	-0.0%	0.3%	0.3%	0.3%	0.1%	0.1%	0.2%
EBITDA Margin %	0.3%	0.3%	0.3%	0.3%	-0.0%	0.3%	0.4%	0.1%	0.1%	0.2%	0.3%
Net Margin %	0.2%	0.2%	0.2%	0.2%	-0.1%	0.2%	0.2%	0.1%	-0.0%	0.1%	0.1%
FCF Margin %	-	-	-	-	-	-	22.6%	7.0%	18.3%	19.0%	16.4%
ROE %	0.1%	0.0%	0.1%	0.1%	-0.1%	0.1%	0.1%	0.1%	-0.0%	0.3%	0.1%
ROA %	0.1%	0.0%	0.1%	0.1%	-0.0%	0.1%	0.0%	0.0%	-0.0%	0.1%	0.0%
ROIC %	0.1%	2.3%	9.4%	9.7%	-0.6%	8.5%	8.3%	8.1%	1.9%	5.4%	5.5%

Key Ratio

TTM

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

Gross Margin %

0.6%

0.2%

0.6%

Operating Margin %

0.3%

-0.0%

0.3%

0.1%

0.2%

EBITDA Margin %

0.3%

-0.0%

0.3%

0.4%

0.1%

0.2%

0.3%

Net Margin %

0.2%

-0.1%

0.2%

0.1%

-0.0%

0.1%

FCF Margin %

22.6%

7.0%

18.3%

19.0%

16.4%

ROE %

0.1%

0.0%

0.1%

-0.1%

0.1%

-0.0%

0.3%

0.1%

ROA %

0.1%

0.0%

0.1%

-0.0%

0.1%

0.0%

-0.0%

0.1%

0.0%

ROIC %

0.1%

2.3%

9.4%

9.7%

-0.6%

8.5%

8.3%

8.1%

1.9%

5.4%

5.5%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$1.1B	$1.1B	$1.1B	$1.1B	$1.1B	$943M	$2.9B	$976M	$1.0B	$882M	$806M	$715M
	—	$503M	$501M	$502M	$466M	—	—	—	—	—	—	—
	$607M	$634M	$624M	$625M	$621M	$547M	$552M	$556M	$577M	$500M	$467M	$406M
Gross Margin	55.6%	55.8%	55.5%	55.5%	57.1%	58.0%	57.3%	56.9%	18.5%	56.7%	58.0%	56.8%
	—	—	—	—	—	$35M	$33M	$38M	$40M	$34M	$33M	$27M
Total Operating Expenses	—	$298M	$282M	$648M	$291M	—	—	—	—	—	—	—
	$318M	$337M	$342M	-$22M	$330M	$297M	$291M	$68M	$216M	$206M	$260M	$208M
EBIT	$318M	$337M	$342M	-$22M	$330M	$297M	$291M	$68M	$216M	$206M	$260M	$208M
EBITDA	$318M	$337M	$342M	-$22M	$330M	$334M	$322M	$105M	$256M	$240M	$293M	$235M
Operating Margin	29.2%	29.6%	30.4%	-2.0%	30.4%	31.5%	30.2%	6.9%	6.9%	23.3%	32.3%	29.0%
EBITDA Margin	29.2%	29.6%	30.4%	-2.0%	30.4%	35.4%	11.2%	10.7%	24.6%	27.2%	36.3%	32.9%
	—	$2M	$5M	—	—	$95M	$99M	$105M	$109M	$95M	$103M	$81M
	—	$284M	$276M	-$94M	$262M	—	—	—	—	—	—	—
Income Tax Expense	—	$70M	$67M	-$12M	$57M	$39M	$49M	-$2M	-$232M	$41M	$57M	$49M
	$191M	$215M	$209M	-$82M	$205M	$165M	$142M	-$36M	$340M	$69M	$100M	$78M
Net Margin	17.5%	18.9%	18.6%	-7.3%	18.9%	17.5%	14.8%	-3.7%	10.9%	7.9%	12.4%	10.9%
	$0.98	$4.32	$4.21	$-1.65	$4.09	$3.28	$2.81	$-0.69	$6.40	$1.31	$1.89	$1.50
Diluted EPS	$0.98	$4.29	$4.17	$-1.65	$4.04	$3.28	$2.81	$-0.69	$6.40	$1.31	$1.89	$1.50
Weighted Avg Basic	—	50M	50M	50M	50M	—	—	—	—	—	—	—
Weighted Avg Diluted	—	50M	50M	50M	51M	—	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$1.1B

$943M

$2.9B

$976M

$1.0B

$882M

$806M

$715M

—

$503M

$501M

$502M

$466M

—

$607M

$634M

$624M

$625M

$621M

$547M

$552M

$556M

$577M

$500M

$467M

$406M

Gross Margin

55.6%

55.8%

55.5%

57.1%

58.0%

57.3%

56.9%

18.5%

56.7%

58.0%

56.8%

—

$35M

$33M

$38M

$40M

$34M

$33M

$27M

Total Operating Expenses

—

$298M

$282M

$648M

$291M

—

$318M

$337M

$342M

-$22M

$330M

$297M

$291M

$68M

$216M

$206M

$260M

$208M

EBIT

$318M

$337M

$342M

-$22M

$330M

$297M

$291M

$68M

$216M

$206M

$260M

$208M

EBITDA

$318M

$337M

$342M

-$22M

$330M

$334M

$322M

$105M

$256M

$240M

$293M

$235M

Operating Margin

29.2%

29.6%

30.4%

-2.0%

30.4%

31.5%

30.2%

6.9%

23.3%

32.3%

29.0%

EBITDA Margin

29.2%

29.6%

30.4%

-2.0%

30.4%

35.4%

11.2%

10.7%

24.6%

27.2%

36.3%

32.9%

—

$2M

$5M

—

$95M

$99M

$105M

$109M

$95M

$103M

$81M

—

$284M

$276M

-$94M

$262M

—

Income Tax Expense

—

$70M

$67M

-$12M

$57M

$39M

$49M

-$2M

-$232M

$41M

$57M

$49M

$191M

$215M

$209M

-$82M

$205M

$165M

$142M

-$36M

$340M

$69M

$100M

$78M

Net Margin

17.5%

18.9%

18.6%

-7.3%

18.9%

17.5%

14.8%

-3.7%

10.9%

7.9%

12.4%

10.9%

$0.98

$4.32

$4.21

$-1.65

$4.09

$3.28

$2.81

$-0.69

$6.40

$1.31

$1.89

$1.50

Diluted EPS

$0.98

$4.29

$4.17

$-1.65

$4.04

$3.28

$2.81

$-0.69

$6.40

$1.31

$1.89

$1.50

Weighted Avg Basic

—

50M

—

Weighted Avg Diluted

—

50M

51M

—

Prestige Consumer Healthcare Inc. (PBH) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does Prestige Consumer Healthcare Inc. Do?

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York. Prestige Consumer Healthcare Inc. (PBH) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Ronald M. Lombardi and employs approximately 540 people, headquartered in TARRYTOWN, New York. With a market capitalization of $2.7B, PBH is one of the notable companies in the Healthcare sector.

Prestige Consumer Healthcare Inc. (PBH) Stock Rating — Reduce (April 2026)

As of April 2026, Prestige Consumer Healthcare Inc. receives a Reduce rating with a composite score of 40.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.PBH ranks #2,870 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Prestige Consumer Healthcare Inc. ranks #402 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PBH Stock Price and 52-Week Range

Prestige Consumer Healthcare Inc. (PBH) currently trades at $56.55. The stock lost $0.21 (0.4%) in the most recent trading session. The 52-week high for PBH is $89.37, which means the stock is currently trading -36.7% from its annual peak. The 52-week low is $57.25, putting the stock -1.2% above its annual trough. Recent trading volume was 341K shares, suggesting relatively thin trading activity.

Is PBH Overvalued or Undervalued? — Valuation Analysis

Prestige Consumer Healthcare Inc. (PBH) carries a value factor score of 48/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 13.80x, compared to the Healthcare sector average of 23.63x — a discount of 42%. The price-to-book ratio stands at 1.44x, versus the sector average of 2.75x. The price-to-sales ratio is 2.41x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, PBH trades at 11.52x EV/EBITDA, versus 6.34x for the sector.

Overall, PBH's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

Prestige Consumer Healthcare Inc. Profitability — ROE, Margins, and Quality Score

Prestige Consumer Healthcare Inc. (PBH) earns a quality factor score of 49/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 10.4%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 5.5% versus the sector average of -33.1%.

On a margin basis, Prestige Consumer Healthcare Inc. reports gross margins of 55.6%, compared to 71.5% for the sector. The operating margin is 29.2% (sector: -66.1%). Net profit margin stands at 17.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 6.1% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PBH Debt, Balance Sheet, and Financial Health

Prestige Consumer Healthcare Inc. has a debt-to-equity ratio of 56.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.11x, indicating strong short-term liquidity. Total debt on the balance sheet is $1.03B.

PBH has a beta of 0.48, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Prestige Consumer Healthcare Inc. is 72/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

Prestige Consumer Healthcare Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Prestige Consumer Healthcare Inc. reported revenue of $1.09B and earnings per share (EPS) of $0.98. Net income for the quarter was $191M. Gross margin was 55.6%. Operating income came in at $318M.

In Q3 2026, Prestige Consumer Healthcare Inc. reported revenue of $283M and earnings per share (EPS) of $0.98. Net income for the quarter was $47M. Gross margin was 55.5%. Operating income came in at $82M.

In Q2 2026, Prestige Consumer Healthcare Inc. reported revenue of $274M and earnings per share (EPS) of $0.86. Net income for the quarter was $42M. Gross margin was 55.3%. Revenue grew -3.4% year-over-year compared to Q2 2025. Operating income came in at $80M.

In Q1 2026, Prestige Consumer Healthcare Inc. reported revenue of $250M and earnings per share (EPS) of $0.96. Net income for the quarter was $47M. Gross margin was 56.2%. Revenue grew -6.6% year-over-year compared to Q1 2025. Operating income came in at $72M.

Over the past 8 quarters, Prestige Consumer Healthcare Inc. has experienced revenue contraction from $1.13B to $1.09B. Investors analyzing PBH stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PBH Dividend Yield and Income Analysis

Prestige Consumer Healthcare Inc. (PBH) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PBH Momentum and Technical Analysis Profile

Prestige Consumer Healthcare Inc. (PBH) has a momentum factor score of 29/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 31/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 11/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

PBH vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Prestige Consumer Healthcare Inc. (PBH) ranks #402 out of 838 stocks based on the Blank Capital composite score. This places PBH in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PBH against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PBH vs S&P 500 (SPY) comparison to assess how Prestige Consumer Healthcare Inc. stacks up against the broader market across all factor dimensions.

PBH Next Earnings Date

No upcoming earnings date has been announced for Prestige Consumer Healthcare Inc. (PBH) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PBH? — Investment Thesis Summary

The quantitative profile for Prestige Consumer Healthcare Inc. suggests caution. Momentum is weak at 29/100, a headwind for near-term performance. Low volatility (stability score 72/100) reduces downside risk.

In summary, Prestige Consumer Healthcare Inc. (PBH) earns a Reduce rating with a composite score of 40.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PBH stock.

Related Resources for PBH Investors

Explore more research and tools: PBH vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PBH head-to-head with peers: PBH vs AZN, PBH vs SLGL, PBH vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Australia toma medidas contra la publicidad de casas de apuestas y juegos

Australia PM Albanese announces crackdown on gambling advertising

Health Care Down Amid Regulatory Fears -- Health Care Roundup

Why Prestige Consumer Healthcare (PBH) Is Down 5.8% After Heightened Regulatory Scrutiny On Its OTC Portfolio

Has Prestige Consumer Healthcare (PBH) Fallen Too Far After Its 32% One-Year Share Price Drop

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

Prestige Consumer Healthcare Inc. (PBH) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does Prestige Consumer Healthcare Inc. Do?

Prestige Consumer Healthcare Inc. (PBH) Stock Rating — Reduce (April 2026)

PBH Stock Price and 52-Week Range

Is PBH Overvalued or Undervalued? — Valuation Analysis

Prestige Consumer Healthcare Inc. Profitability — ROE, Margins, and Quality Score

PBH Debt, Balance Sheet, and Financial Health

Prestige Consumer Healthcare Inc. Revenue and Earnings History — Quarterly Trend

PBH Dividend Yield and Income Analysis

PBH Momentum and Technical Analysis Profile

PBH vs Competitors — Healthcare Sector Ranking and Peer Comparison

PBH Next Earnings Date

Should You Buy PBH? — Investment Thesis Summary

Related Resources for PBH Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Australia toma medidas contra la publicidad de casas de apuestas y juegos

Australia PM Albanese announces crackdown on gambling advertising

Health Care Down Amid Regulatory Fears -- Health Care Roundup

Why Prestige Consumer Healthcare (PBH) Is Down 5.8% After Heightened Regulatory Scrutiny On Its OTC Portfolio

Has Prestige Consumer Healthcare (PBH) Fallen Too Far After Its 32% One-Year Share Price Drop